BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35263755)

  • 21. Reduced Effectiveness and Comparable Safety in Biweekly
    Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
    Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency.
    Chatelain P; Malievskiy O; Radziuk K; Senatorova G; Abdou MO; Vlachopapadopoulou E; Skorodok Y; Peterkova V; Leff JA; Beckert M;
    J Clin Endocrinol Metab; 2017 May; 102(5):1673-1682. PubMed ID: 28201598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency.
    Loftus J; Miller BS; Parzynski CS; Alvir J; Chen Y; Jhingran P; Gupta A; DeKoven M; Divino V; Tse J; He J; Wajnrajch M
    Endocr Pract; 2022 Jun; 28(6):565-571. PubMed ID: 35263660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity.
    Alkhatib EH; Dauber A; Estrada DE; Majidi S
    Horm Res Paediatr; 2023; 96(5):542-546. PubMed ID: 37015214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.
    Garner T; Clayton P; Højby M; Murray P; Stevens A
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1214-1221. PubMed ID: 38066644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.
    Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG;
    J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis.
    Zhu J; Yuan K; Rana S; Jakki SL; Bhat AS; Liang L; Wang C
    Sci Rep; 2024 Apr; 14(1):8061. PubMed ID: 38580693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
    Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
    J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol).
    Schnabel D; Kreitschmann-Andermahr I; Strasburger CJ; Pittrow D; Pausch C; Woelfle J;
    Orphanet J Rare Dis; 2023 May; 18(1):112. PubMed ID: 37165422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
    Liang Y; Zhang C; Wei H; Du H; Zhang G; Yang Y; Zhang H; Gong H; Li P; Song F; Xu Z; He R; Zhou W; Zheng H; Sun L; Luo X
    Front Endocrinol (Lausanne); 2022; 13():922304. PubMed ID: 36034448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Overall Safety of NutropinAq
    Coutant R; Bosch Muñoz J; Dumitrescu CP; Schnabel D; Sert C; Perrot V; Dattani M
    Front Endocrinol (Lausanne); 2021; 12():676083. PubMed ID: 34113318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
    Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
    BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.
    Otsuka F; Takahashi Y; Tahara S; Ogawa Y; Højby Rasmussen M; Takano K
    Clin Endocrinol (Oxf); 2020 Nov; 93(5):620-628. PubMed ID: 32603494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
    Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lonapegsomatropin (Skytrofa) for growth hormone deficiency.
    Med Lett Drugs Ther; 2022 Feb; 64(1643):20-22. PubMed ID: 35134048
    [No Abstract]   [Full Text] [Related]  

  • 36. Growth Responses During 3 Years of Growth Hormone Treatment in Children and Adolescents With Growth Hormone Deficiency: Comparison Between Idiopathic, Organic and Isolated Growth Hormone Deficiency, and Multiple Pituitary Hormone Deficiency.
    Lim HH; Kim YM; Lee GM; Yu J; Han HS; Yu J
    J Korean Med Sci; 2022 Mar; 37(11):e90. PubMed ID: 35315601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study.
    Maniatis AK; Carakushansky M; Galcheva S; Prakasam G; Fox LA; Dankovcikova A; Loftus J; Palladino AA; de Los Angeles Resa M; Turich Taylor C; Dattani MT; Lebl J
    J Endocr Soc; 2022 Oct; 6(10):bvac117. PubMed ID: 36101713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
    Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
    J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature.
    Yuan J; Fu J; Wei H; Zhang G; Xiao Y; Du H; Gu W; Li Y; Chen L; Luo F; Zhong Y; Gong H
    Front Endocrinol (Lausanne); 2022; 13():864908. PubMed ID: 35573994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.